DK3200783T3 - Behandling af erytromelalgi - Google Patents

Behandling af erytromelalgi Download PDF

Info

Publication number
DK3200783T3
DK3200783T3 DK15790622.3T DK15790622T DK3200783T3 DK 3200783 T3 DK3200783 T3 DK 3200783T3 DK 15790622 T DK15790622 T DK 15790622T DK 3200783 T3 DK3200783 T3 DK 3200783T3
Authority
DK
Denmark
Prior art keywords
erytromelalgy
treatment
Prior art date
Application number
DK15790622.3T
Other languages
English (en)
Inventor
Valerie Morisset
Original Assignee
Convergence Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals filed Critical Convergence Pharmaceuticals
Application granted granted Critical
Publication of DK3200783T3 publication Critical patent/DK3200783T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15790622.3T 2014-10-03 2015-10-02 Behandling af erytromelalgi DK3200783T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417497.3A GB201417497D0 (en) 2014-10-03 2014-10-03 Novel use
PCT/GB2015/052885 WO2016051194A1 (en) 2014-10-03 2015-10-02 Erythromelalgia treatment

Publications (1)

Publication Number Publication Date
DK3200783T3 true DK3200783T3 (da) 2019-08-05

Family

ID=51946794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15790622.3T DK3200783T3 (da) 2014-10-03 2015-10-02 Behandling af erytromelalgi

Country Status (15)

Country Link
US (2) US10231950B2 (da)
EP (1) EP3200783B1 (da)
CY (1) CY1122418T1 (da)
DK (1) DK3200783T3 (da)
ES (1) ES2751688T3 (da)
GB (1) GB201417497D0 (da)
HR (1) HRP20191434T1 (da)
HU (1) HUE047940T2 (da)
LT (1) LT3200783T (da)
PL (1) PL3200783T3 (da)
PT (1) PT3200783T (da)
RS (1) RS59479B1 (da)
SI (1) SI3200783T1 (da)
SM (1) SMT201900723T1 (da)
WO (1) WO2016051194A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417497D0 (en) * 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
SG11201903667XA (en) * 2016-11-02 2019-05-30 Biogen Inc Novel dosage regimen
JP2021521227A (ja) * 2018-04-16 2021-08-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 神経障害性疼痛を処置する方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
CA2134552A1 (en) 1992-04-27 1993-11-11 George D. Sorenson Detection of gene sequences in biological fluids
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US8093268B2 (en) * 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
US9376429B2 (en) * 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
EP3666274A1 (en) * 2013-03-15 2020-06-17 Purdue Pharma LP Carboxamide derivatives and use thereof
GB201409851D0 (en) * 2014-06-03 2014-07-16 Convergence Pharmaceuticals Diagnostic method
GB201417497D0 (en) * 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
KR102412146B1 (ko) * 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제

Also Published As

Publication number Publication date
HUE047940T2 (hu) 2020-05-28
EP3200783A1 (en) 2017-08-09
PL3200783T3 (pl) 2020-01-31
ES2751688T3 (es) 2020-04-01
PT3200783T (pt) 2019-08-21
HRP20191434T1 (hr) 2020-10-02
GB201417497D0 (en) 2014-11-19
WO2016051194A1 (en) 2016-04-07
US20170304264A1 (en) 2017-10-26
EP3200783B1 (en) 2019-07-31
RS59479B1 (sr) 2019-12-31
SI3200783T1 (sl) 2020-03-31
CY1122418T1 (el) 2021-01-27
US10231950B2 (en) 2019-03-19
SMT201900723T1 (it) 2020-03-13
US20190388391A1 (en) 2019-12-26
LT3200783T (lt) 2019-09-10

Similar Documents

Publication Publication Date Title
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3180331T3 (da) Polymorfer af selinexor
DK3231444T3 (da) Ny behandling
DK3132009T3 (da) Fremgangsmåde
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3307267T3 (da) Behandling af multipel sklerose
DK3283210T3 (da) Fremgangsmåde
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3237621T5 (da) Varianter af human alpha-galactosidase
DK3418273T3 (da) Derivater af flavagliner
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
IL254825A0 (en) Methods of treatment with taselisib
DK3151814T3 (da) Behandling af en hudlæsion